Literature DB >> 11717610

Validation of a specific activity questionnaire to estimate exercise tolerance in patients referred for exercise testing.

J Myers1, D Bader, R Madhavan, V Froelicher.   

Abstract

BACKGROUND: Physical activity and symptom questionnaires have been used as surrogates for exercise testing to estimate a patient's functional capacity and to individualize an exercise testing protocol in accordance with exercise testing guidelines. To validate these approaches, they must be compared with measured oxygen uptake (peak VO (2)).
METHODS: Before exercise testing was performed, a brief, self-administered questionnaire (Veterans Specific Activity Questionnaire [VSAQ]) was given to 337 patients referred for exercise testing for clinical reasons. The VSAQ was used to estimate exercise tolerance on the basis of symptoms during daily activities to individualize ramp rates on the treadmill so that the test duration would be approximately 10 minutes. Clinical and demographic variables were added to the VSAQ responses in a stepwise regression model to determine their ability to predict both directly measured peak VO (2) and peak metabolic equivalents (METs) predicted from the treadmill workload.
RESULTS: The mean exercise time was 9.6 +/- 3 minutes. Responses to the VSAQ and age were the strongest predictors of both measured and predicted exercise capacity. Small but significant contributions to the explanation of variance in both measured and estimated METs were made by resting heart rate, forced expiratory volume in 1 second expressed as a percentage of normal, exercise capacity predicted for age, and body mass index. The multiple R values from the regression equations for measured and estimated METs were 0.58 and 0.72, respectively.
CONCLUSIONS: Estimating a patient's symptoms associated with daily activities along with age are the strongest predictors of a patient's exercise tolerance. The VSAQ, combined with pretest clinical data, predicts the estimated MET value from treadmill speed and grade better than directly measured METs do. When used for estimating a patient's symptom limits to individualize ramp rates on a treadmill, this approach yields an appropriate test duration in accordance with recent exercise testing guidelines.

Entities:  

Mesh:

Year:  2001        PMID: 11717610     DOI: 10.1067/mhj.2001.118740

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  22 in total

1.  Validity of an exercise test based on habitual gait speed in mobility-limited older adults.

Authors:  Xin Li; Daniel E Forman; Dan K Kiely; Sharon LaRose; Ronald Hirschberg; Walter R Frontera; Jonathan F Bean
Journal:  Arch Phys Med Rehabil       Date:  2012-02       Impact factor: 3.966

2.  Correlation of subjective questionnaires with cardiac function as determined by exercise testing in a pediatric population.

Authors:  Rebekah Burns; Inger Olson; Jeffrey Kazmucha; Raymond Balise; Rita Chin; Clifford Chin
Journal:  Pediatr Cardiol       Date:  2010-09-03       Impact factor: 1.655

3.  Association of physical function and performance with peak VO2 in elderly patients with end stage kidney disease.

Authors:  Jonathan Myers; Khin N Chan; Yu Chen; Yiming Lit; Payam Massaband; B Jenny Kiratli; Jane C Tan; Ralph Rabkin
Journal:  Aging Clin Exp Res       Date:  2021-03-08       Impact factor: 3.636

4.  A simple tool to predict exercise capacity of obese patients with ischaemic heart disease.

Authors:  L A Gondoni; A Liuzzi; A M Titon; O Taronna; F Nibbio; P Ferrari; G Leonetti
Journal:  Heart       Date:  2005-12-09       Impact factor: 5.994

5.  Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.

Authors:  Carlos H Martinez; Susan Murray; R Graham Barr; Eugene Bleecker; Russell P Bowler; Stephanie A Christenson; Alejandro P Comellas; Christopher B Cooper; David Couper; Gerard J Criner; Jeffrey L Curtis; Mark T Dransfield; Nadia N Hansel; Eric A Hoffman; Richard E Kanner; Eric Kleerup; Jerry A Krishnan; Stephen C Lazarus; Nancy K Leidy; Wanda O'Neal; Fernando J Martinez; Robert Paine; Stephen I Rennard; Donald P Tashkin; Prescott G Woodruff; MeiLan K Han
Journal:  Ann Am Thorac Soc       Date:  2017-05

6.  Prediction of maximal oxygen uptake by bioelectrical impedance analysis in overweight adolescents.

Authors:  M D Roberts; B Drinkard; L M Ranzenhofer; C G Salaita; N G Sebring; S M Brady; C Pinchbeck; J Hoehl; L B Yanoff; D M Savastano; J C Han; J A Yanovski
Journal:  J Sports Med Phys Fitness       Date:  2009-09       Impact factor: 1.637

7.  Relationships of obesity and fat distribution with atherothrombotic risk factors: baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors:  Jeanine B Albu; Jiang Lu; Arshag D Mooradian; Ronald J Krone; Richard W Nesto; Marty H Porter; Jamal S Rana; William J Rogers; Burton E Sobel; Sheldon H Gottlieb
Journal:  Obesity (Silver Spring)       Date:  2009-10-29       Impact factor: 5.002

8.  Effect of oral anabolic steroid on muscle strength and muscle growth in hemodialysis patients.

Authors:  Ouppatham Supasyndh; Bancha Satirapoj; Pornanong Aramwit; Duangkamol Viroonudomphol; Amnart Chaiprasert; Vipa Thanachatwej; Supat Vanichakarn; Joel D Kopple
Journal:  Clin J Am Soc Nephrol       Date:  2012-11-02       Impact factor: 8.237

9.  Telemonitoring based service redesign for the management of uncontrolled hypertension: multicentre randomised controlled trial.

Authors:  Brian McKinstry; Janet Hanley; Sarah Wild; Claudia Pagliari; Mary Paterson; Steff Lewis; Aziz Sheikh; Ashma Krishan; Andrew Stoddart; Paul Padfield
Journal:  BMJ       Date:  2013-05-24

10.  Determination of Best Criteria to Determine Final and Initial Speeds within Ramp Exercise Testing Protocols.

Authors:  Sidney C da Silva; Walace D Monteiro; Felipe A Cunha; Jonathan Myers; Paulo T V Farinatti
Journal:  Pulm Med       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.